このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Visual Instillation of Sphenopalatine-block Intervention for ONgoing Migraine (VISION)

2026年8月10日 更新者:Association of Migraine Disorders

The goal of this double-blinded, randomized placebo controlled clinical trial is to to see if using a numbing medicine (lidocaine) on certain areas inside the nose can help with headaches, neck pain, facial pain and pressure, and other symptoms. It also aims to understand the pathophysiology that causes these symptoms.

The main questions it aims to answer are:

  1. Is applying numbing medication directly to the sphenopalatine ganglion (SPG) area, while watching through the scope to make sure it's in the right place, a workable and effective way to treat migraine headaches immediately and 24 hours?
  2. Is applying numbing medication directly to the sphenopalatine ganglion (SPG) area, while watching through the scope to make sure it's in the right place, a workable and effective way to improve patient-reported outcomes?

The 2-month study requires:

  • One virtual visit (on the computer)
  • One visit to the office for placement of the numbing medicine under direct vision
  • Daily headache diary entries that take less than two minutes to complete

調査の概要

研究の種類

介入

入学 (推定)

74

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Massachusetts
      • Springfield、Massachusetts、アメリカ、01107

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion criteria:

  • Aged 18 years or older
  • Any race
  • Any gender
  • At least 2 of 3 positives (a, b, c) below on the ID Migraine Screener from the American Headache Society:

    1. Photophobia
    2. Inability to function
    3. Nausea
  • At least 3 months of patient-reported episodic or persistent discomfort, pain, or pressure in the anatomic distribution of the paranasal sinuses, orbits, or nasal cavities.
  • The patient experiences at least 10 days of headaches and/or FPP within a 30-day period, during the run-in phase.
  • No evidence of abnormal sinus findings on imaging [paranasal sinus CT, including cone beam imaging, or MRI (MRI images must include all paranasal sinuses) obtained when symptomatic in the last 12 months prior to presentation. Normal imaging findings included isolated mucus retention cysts 2 cm or less in size and minimal non-circumferential (isolated areas) mucosal thickening (3mm or less).
  • Normal endoscopy if performed prior to enrollment, defined as the absence of purulent (opaque - white or other discolored - secretions) at the middle meatus or sphenoethmoid recess or nasal polyp disease.
  • Daily access to a cell phone that can function with the study mobile application
  • For women of child bearing potential: not pregnant and using a method of contraception during the duration of the study.
  • The patient can be taking interventional and preventive medications and other treatments before and during the study period, including new medications which will be tracked. The clinical coordinator will ask the patient to refrain from taking any abortive medication, cannabis, and psilocybin 24 hours prior to the procedure visit.

Exclusion criteria:

  • Prior endoscopic sinus surgery within the 3 months prior to enrollment.
  • Nasal endoscopy if performed prior to enrollment shows severe signs of mucosal infection, (mucopurulent drainage) or nasal polyposis.
  • A history of anterior skull base neoplasia.
  • Nasal endoscopy if performed prior to enrollment does not allow visualization of the middle turbinate on endoscopy bilaterally after application of a topical decongestant.
  • Signs of active or chronic sinusitis on CT (>3mm mucosal thickening or air fluid level in any paranasal sinus.)
  • The patient cannot tolerate the use of topical anesthetics or intranasal endoscopy without sedation or general anesthesia
  • Unable to see the middle meatus with either a nasal speculum or an endoscope
  • Allergy to lidocaine or other local anesthetics (tertiary amine class 1b).
  • Is currently using a schedule II narcotic for migraine pain.
  • Current cocaine use or cocaine use within the last 30 days.
  • Currently immunocompromised
  • History or evidence of any other unstable or clinically significant medical condition that in the opinion of the sponsor-investigator/ Principal Investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
  • Has received any investigational agent within 30 days of enrollment.
  • Plans to participate in a concurrent clinical trial.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Topical lidocaine endoscopically-guided intranasal nerve block
Topical solution of 4% lidocaine on small cotton pledgets with be placed endoscopically at the posterior root of the middle turbinate and in the anterior ethmoid nerve region bilaterally for Sphenopalatine Ganglion Block (SPG) block with anterior ethmoid (AE) block.
A rigid endoscopic technique utilizing a cotton pledget as a delivery vehicle of the topical lidocaine allows direct visualization of the target.
プラセボコンパレーター:Placebo (saline) endoscopically-guided intranasal nerve block
Topical solution of saline on small cotton pledgets with be placed endoscopically at the posterior root of the middle turbinate and in the anterior ethmoid nerve region bilaterally for Sphenopalatine Ganglion Block (SPG) block with anterior ethmoid (AE) block.
A rigid endoscopic technique utilizing cotton pledget as a delivery vehicle of the topical saline allows direct visualization of the target.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Acute headache pain
時間枠:Immediately before (pre-treatment) and after the endoscopy procedure at Visit 2, approximately 1 month after enrollment.
Acute headache pain will be measured using a 0 to 10 Likert scale (0 representing No Pain, and 10 representing the worst pain possible), before (pre-treatment) and after the endoscopy procedure (post-treatment) at 15, 30, 60 min and 24 hours.
Immediately before (pre-treatment) and after the endoscopy procedure at Visit 2, approximately 1 month after enrollment.
Acute facial pain or pressure
時間枠:Immediately before (pre-treatment) and after the endoscopy procedure at Visit 2, approximately 1 month after enrollment.
Acute facial pain or pressure will be measured using a 0 to 10 Likert scale (0 representing No Pain, and 10 representing the worst pain possible), before (pre-treatment) and after the endoscopy procedure (post-treatment) at 15, 30, 60 min and 24 hours.
Immediately before (pre-treatment) and after the endoscopy procedure at Visit 2, approximately 1 month after enrollment.
Acute neck pain
時間枠:Immediately before (pre-treatment) and after the endoscopy procedure at Visit 2, approximately 1 month after enrollment.
Acute neck pain will be measured using a 0 to 10 Likert scale (0 representing No Pain, and 10 representing the worst pain possible), before (pre-treatment) and after the endoscopy procedure (post-treatment) at 15, 30, 60 min and 24 hours.
Immediately before (pre-treatment) and after the endoscopy procedure at Visit 2, approximately 1 month after enrollment.

二次結果の測定

結果測定
メジャーの説明
時間枠
Headache days per month
時間枠:Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.
Daily headache pain recorded in a mobile application. Recorded as binary (Yes/No) and rated using a 0 to 10 Likert scale (0 representing No Pain, and 10 representing the worst pain possible).
Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.
Facial pain or pressure days per month
時間枠:Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.
Daily facial pain or pressure recorded in a mobile application. Recorded as binary (Yes/No) and rated using a 0 to 10 Likert scale (0 representing No Pain or pressure, and 10 representing the worst pain or pressure possible).
Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.
Neck pain days per month
時間枠:Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.
Daily neck pain recorded in a mobile application. Recorded as binary (Yes/No) and rated using a 0 to 10 Likert scale (0 representing No Pain, and 10 representing the worst pain possible).
Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.
Sinonasal Outcome Test- 22 (SNOT-22)
時間枠:Immediately before the treatment at 1 month and again 1 month after treatment.
SNOT-22 is A validated 22-item questionnaire that measures the health-related quality of life (HRQoL) of patients with chronic rhinosinusitis (CRS). The SNOT-22 is scored by adding the individual values of 22 symptom and quality-of-life items. Each item is graded on a scale from 0 to 5, yielding a total cumulative score between 0 and 110, where higher numbers reflect more severe symptoms and a greater impact on health.
Immediately before the treatment at 1 month and again 1 month after treatment.
Migraine Disability Assessment (MIDAS)
時間枠:Immediately before the treatment at 1 month and again 1 month after treatment.

MIDAS is a valid and reliable short questionnaire for assessment of headache related disability. Respondents will enter the total number of days affected in the last one month for:

Work or school: Days missed. Work or school productivity: Days where productivity was reduced by half or more.

Household work: Days missed. Household work productivity: Days where productivity was reduced by half or more.

Family, social, or leisure activities: Days missed.

Immediately before the treatment at 1 month and again 1 month after treatment.

その他の成果指標

結果測定
メジャーの説明
時間枠
Additional headache symptoms
時間枠:Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.
Additional headache symptoms recorded in a mobile application. Recorded as binary (Yes/No) and rated using a 0 to 10 Likert scale (0 representing No Pain, and 10 representing the worst pain possible).
Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.
Rescue medications
時間枠:Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.
Rescue medication needed, recorded in a mobile application. Recorded as binary (Yes/No).
Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Jerry Schreibstein, MD、Ear, Nose, & Throat Surgeons of Western New England

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年9月1日

一次修了 (推定)

2028年9月1日

研究の完了 (推定)

2028年9月1日

試験登録日

最初に提出

2026年8月1日

QC基準を満たした最初の提出物

2026年8月10日

最初の投稿 (実際)

2026年8月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年8月14日

QC基準を満たした最後の更新が送信されました

2026年8月10日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する